Diabetes Clinical Trials in North Carolina

Showing 281-292 of 292 trials

A Study to Evaluate Safety and Efficacy of PHX1149T in Subjects With Type 2 Diabetes Mellitus

NCT00482950

This study is to test the efficacy and safety of PHX1149T in combination with metformin, a glitazone, or metformin and a glitazone in subjects with Type 2 diabetes for 12 weeks. After completing the 12 week double blind part of the study, subjects can enter an open label extension study

Type 2 Diabetes Mellitus

Phenomix400 participantsStarted Apr 2007

Chula Vista, California, United States • Fullerton, California, United States • Long Beach, California, United States +23 more locations

COMPLETEDPHASE241 miles

Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes

NCT00110864

This study is designed to evaluate the safety and efficacy of PN2034 in insulin-dependent type 2 diabetics as measured by the change in average daily insulin dose from baseline to week 12. The effects of PN2034 on HbA1c, fasting plasma glucose (FPG), and lipid levels will also be measured.

Type 2 Diabetes Mellitus

Wellstat Therapeutics90 participantsStarted May 2005

Waterbury, Connecticut, United States • Hollywood, Florida, United States • Longwood, Florida, United States +15 more locations

A Study to Evaluate Safety and Efficacy of PHX1149T in Subjects With Type 2 Diabetes Mellitus

Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes

Diabetes Trials in Other Cities

Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients

A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control

An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes

Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose

Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to the American Diabetic Association (ADA) Diabetes Meal Plan on Body Weight and Satiety in Diabetic Women

Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)

A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes

Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients

GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate

Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus

Other Conditions in North Carolina